Author Archive: Jeremy Parkinson

Goldman: Forget Trump Rally, Now Look At Fundamentals

Goldman: Forget Trump Rally, Now Look At Fundamentals

As a market built on Trump rally optimism meets a legislative reality that might not be able to get much done, including any meaningful tax reform, where does one invest in a market environment which Goldman Sachs now categorizes as “Gridlock” in the subtitle of a “Where to Invest Now” report? With median stock prices trading […]
Atlanta Fed Slashes Q1 GDP Forecast To Just 0.5%, Lowest In Three Years

Atlanta Fed Slashes Q1 GDP Forecast To Just 0.5%, Lowest In Three Years

Just over two months ago, the Atlanta Fed “calculated” that Q1 GDP was going to be a pleasant 3.4%, confirming that the Fed had made the correct decision by hiking not only in December, but also last month. Since then, the Fed’s own GDP estimate has crashed in almost linear fashion, and as of this […]
Retail Sales Unexpectedly Decline, Revisions Even Worse

Retail Sales Unexpectedly Decline, Revisions Even Worse

There are several economic reports out today, none of them any good, especially retail sales, the most important of the reports. Weakness was expected in this corner but not by those who still insist the economy is strengthening. Retail sales declined 0.2% in March vs an Econoday consensus reading of 0.0%. Moreover, the Census Bureau […]
Oil Closes Higher On International Energy Report

Oil Closes Higher On International Energy Report

On Thursday, oil prices closed slightly higher after a very bullish international energy report. Optimism that an On Thursday, oil prices closed slightly higher after a very bullish international energy report. Optimism that an extension to the output cut deal will be put in place also helped keep oil prices higher.output cut deal will be […]
EUR/USD Forecast Apr. 17 – 21

EUR/USD Forecast Apr. 17 – 21

EUR/USD managed to rebound from the lows ahead of Easter, getting back to the range. Will it stay there? Inflation figures and PMIs stand out ahead of the French elections. Here is an outlook for the highlights of this week and an updated technical analysis for EUR/USD. Tension is rising towards the French elections, with the emergence […]
It’s Time For A “Tactical Rally” In Bond Markets: Deutsche Bank

It’s Time For A “Tactical Rally” In Bond Markets: Deutsche Bank

If last week marked the “throwing in the towel” moment for Deutsche Bank’s Dominic Konstam with regard to the prospect of higher long-end rates, this week looks to mark a complete rethink of his team’s thesis (at least in the near-term). Yes, Konstam’s latest note (out a day early this week to account for the holiday) still […]
Emerging Markets: What Has Changed This Week

Emerging Markets: What Has Changed This Week

Malaysia’s central bank said it will allow investors to fully hedge their currency exposure. Egypt declared a 3-month state of emergency after two deadly church attacks. South Africa’s parliamentary no confidence vote has been delayed Argentina central bank surprised markets with a 150 bp hike to 26.25%. Brazil central bank accelerated the easing cycle with […]
EC
                        
                        Stock Exchange: Three Contrarian Ideas

EC Stock Exchange: Three Contrarian Ideas

Every trader wants to be a contrarian. You get to be the “smart money.” You buy low and sell high. Buy the dips and sell the rips. Contrarians may not always be right, but they certainly get attention. Brett Steenbarger, everyone’s favorite expert on trading, did a study of this in 2006. He compared two […]
Yen Stalls Despite Geopolitical Concerns

Yen Stalls Despite Geopolitical Concerns

Though currently recouping earlier losses, the US Dollar is still poised to end the week on a down note. Meanwhile, the Japanese Yen continues to be pushed higher on escalating geopolitical concerns. Earlier, the US President cautioned that North Korea “will be taken care of” suggesting that more nuclear tests by Pyongyang could be met […]
FDA Rejects Eli Lilly’s Blockbuster Contender Baricitinib

FDA Rejects Eli Lilly’s Blockbuster Contender Baricitinib

The FDA has rejected Eli Lilly’s (NYSE:LLY) blockbuster contender baricitinib, saying that the pharma giant will need to gather more data to determine the proper doses that should be used by patients before regulators can reconsider their decision. Written by John Carroll (ENDpts.com) The kickback marks a stunning setback for…CEO Dave Ricks, who owes investors […]